Petra Hamerlik

Petra Hamerlik

Company: AstraZeneca

Job title: Associate Research Director/Bioscience


PANEL DISCUSSION: An Overview of Emerging Therapeutic Targets 6:05 pm

Examine the current treatment options and emerging targeted therapies If targeted therapies show limited efficacy as single agents, can the combination of several targeted therapies be of benefit to GBM patients? Additional research is urgently required to identify therapeutic targets in GBM: How can the industry design novel therapeutic strategies for the treatment of GBM?Read more

day: Day One

Determine the Functional Interplay Between Aberrant DNA Repair & Cellular Hierarchies in Glioblastoma 3:15 pm

Examine the diverse causes of therapeutic resistance and how hierarchical organization of this disease is assumed a plausible cause of treatment failure, leading to tumor recurrence Assess how DNA damage poses a serious threat to cell survival by compromising both genomic and epigenomic integrity Study results providing mechanistic insights into how SPT6 regulates DNA repair…Read more

day: Day Two

PANEL DISCUSSION: Recognize the Financial Difficulty of Developing Glioblastoma Treatments and Moving Drugs to the Next Phase 11:00 am

Explore the challenges of funding development How can drug developers inspire and attract companies to invest in their novel preclinical glioblastoma development and pipeline? How can the industry come together to overcome the paucity of funding?Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.